What is it about?
A large international effort involving the University of Melbourne, Takeda Pharmaceuticals and other partners to worked to develop a new type of drug that is specific for the malaria parasite (Plasmodium falciparum). These inhibitor compounds target a sophisticated enzyme complex, called the proteasome, that both human cells and plasmodium rely on to break down unneeded or damaged proteins. The team found a compound that is potent, selective, fast-acting, and active at all stages of the malaria parasite’s lifecycle (both inside inside the mosquito and the human host).
Photo by Presley Roozenburg on Unsplash
Why is it important?
Diseases caused by infectious organisms pose an enormous threat to global health, food security and sustainable development. Malaria is one such debilitating disease, causing more than 400,000 deaths each year. Sadly, delays related to the COVID-19 pandemic are expected to impede efforts to treat and prevent malaria. Even more alarmingly, current antimalarial treatments are rapidly losing efficacy due to the development of resistance. New treatments with new modes of action are urgently needed to combat malaria.
Read the Original
This page is a summary of: Design of proteasome inhibitors with oral efficacy in vivo against
and selectivity over the human proteasome, Proceedings of the National Academy of Sciences, September 2021, Proceedings of the National Academy of Sciences, DOI: 10.1073/pnas.2107213118.
You can read the full text:
The following have contributed to this page